ArticleJournal of oncology2010
Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.
Article in Journal of oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.TheScientificWorldJournal · 2012Trial
- Fetal hematopoietic stem cell homing is controlled by VEGF regulating the integrity and oxidative status of the stromal-vascular bone marrow niches.Cell reports · 2021Article
- Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma.Translational oncology · 2020Article
- nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified.Oncology letters · 2019Article
- Sustain, Adapt, and Overcome-Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia.Frontiers in oncology · 2019Review
- The antitumor effect of the novel cancer-specific adenovirus Ad-VEGFR on bladder cancer in vitro and in vivo.International journal of clinical and experimental pathology · 2018Article
- Anti-Vascular Endothelial Growth Factor Effects of Sorafenib and Arsenic Trioxide in Acute Myeloid Leukemia Cell LinesAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production.Oncotarget · 2016Article
- High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.International journal of hematology · 2016Article
- Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome.Molecular diagnosis & therapy · 2016Article
- Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent.Investigational new drugs · 2015Article
- Review
- Role of plasma membrane caveolae/lipid rafts in VEGF-induced redox signaling in human leukemia cells.BioMed research international · 2014Article
- Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma.Cancer cell international · 2014Article
- GVHD after allogeneic haematopoietic SCT for AML: angiogenesis, vascular endothelial growth factor and VEGF receptor expression in the BM.Bone marrow transplantation · 2013Article
- Intracellular and Extracellular miRNAs in Regulation of Angiogenesis Signaling.Current angiogenesis · 2012Article
- [Normal bone marrow and common reactive alterations].Der Pathologe · 2012Review
- Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Cancer metastasis reviews · 2012Review
- P2X7 Receptor Function in Bone-Related Cancer.Journal of osteoporosis · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis is essential for malignant tumor growth. This has been documented for solid tumors, and there is an emerging evidence suggesting that tumor progression of hematolymphoid malignancies also depends on the induction of new blood vessel formation. The most important proangiogenic agent is vascular endothelial growth factor (VEGF), activating VEGF receptors 1 and 2. The available data on angiogenesis in hemato-lymphoid malignancies, such as acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, multiple myeloma, and lymphomas, point towards the significance of autocrine and paracrine VEGF-mediated effects for proliferation and survival of leukemia/lymphoma cells in addition to tumor vascularization. Antiangiogenic strategies have become an important therapeutic modality for solid tumors. Several antiangiogenic agents targeting VEGF-related pathways are also being utilized in clinical trials for the treatment of hemato-lymphoid malignancies, and in some instances these pathways have emerged as promising therapeutic targets. This review summarizes recent advances in the basic understanding of the role of angiogenesis in hemato-lymphoid malignancies and the translation of such basic findings into clinical studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.